Table 3.
Aspirin/Ibuprofen Use and the Risk of Incident Colorectal Adenoma in the PLCO Cancer Screening Trial
| NSAID use (times/month) |
Controls | Incident Adenoma Overall | Advanced | Non-advanced | |||
|---|---|---|---|---|---|---|---|
| Cases | OR (95% CI)* | Cases | OR (95% CI)* | Cases | OR (95% CI)* | ||
| Aspirin ^ | |||||||
| <4 | 11979 | 743 | 1.00 | 181 | 1.00 | 370 | 1.00 |
| 4 - <30 | 2682 | 152 | 0.87 (0.72, 1.04) | 29 | 0.69 (0.47, 1.03) | 76 | 0.87 (0.67, 1.12) |
| ≥30 | 4965 | 326 | 0.92 (0.80, 1.06) | 77 | 0.86 (0.65, 1.13) | 166 | 0.95 (0.78, 1.15) |
| P, trend | 0.12 | 0.07 | 0.48 | ||||
| Ibuprofen ^ | |||||||
| <4 | 16172 | 1027 | 1.00 | 253 | 1.00 | 511 | 1.00 |
| 4 - <30 | 1664 | 106 | 0.98 (0.79, 1.21) | 20 | 0.76 (0.48, 1.21) | 52 | 0.97 (0.72, 1.30) |
| ≥30 | 1790 | 88 | 0.76 (0.60, 0.95) | 14 | 0.48 (0.28, 0.83) | 49 | 0.87 (0.64, 1.18) |
| P, trend | 0.04 | 0.005 | 0.29 | ||||
| Combined use | |||||||
| <4 | 9934 | 623 | 1.00 | 157 | 1.00 | 312 | 1.00 |
| 4 - <30 | 3488 | 225 | 0.97 (0.83, 1.14) | 45 | 0.77 (0.55, 1.08) | 110 | 0.95 (0.76, 1.18) |
| 30 - <60 | 3967 | 253 | 0.88 (0.75, 1.02) | 64 | 0.84 (0.62, 1.13) | 129 | 0.90 (0.73, 1.11) |
| ≥60 | 2237 | 120 | 0.79 (0.64, 0.97) | 21 | 0.53 (0.33, 0.84) | 61 | 0.82 (0.62, 1.09) |
| P, trend | 0.01 | 0.008 | 0.13 | ||||
*
The Odds Ratio (OR) and 95% confidence interval (CI) were calculated by using unconditional logistic regression and adjusted for study center, race, sex, family history of colorectal cancer, smoking history, body mass index, age at the T3/T5 flexible sigmoidoscopy screen, and the study year of the repeat flexible sigmoidoscopy screen (T3 orT5)
^
Aspirin use is adjusted for Ibuprofen use and vice versa